CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway

Although some breast cancer patients die due to tumor metastasis rather than from the primary tumor, the molecular mechanism of metastasis remains unclear. Therefore, it is necessary to inhibit breast cancer metastasis during cancer treatment. In this case, after designing and synthesizing CTI-2, we...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Junfeng Ke, Wenzhao Han, Fanwei Meng, Feng Guo, Yuhong Wang, Liping Wang
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	breast cancer metastasis EMT MAPK Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/76c7fe7952a64911a36554eb0253dfcd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:76c7fe7952a64911a36554eb0253dfcd
record_format	dspace
spelling	oai:doaj.org-article:76c7fe7952a64911a36554eb0253dfcd2021-11-25T17:54:32ZCTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway10.3390/ijms2222122291422-00671661-6596https://doaj.org/article/76c7fe7952a64911a36554eb0253dfcd2021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12229https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Although some breast cancer patients die due to tumor metastasis rather than from the primary tumor, the molecular mechanism of metastasis remains unclear. Therefore, it is necessary to inhibit breast cancer metastasis during cancer treatment. In this case, after designing and synthesizing CTI-2, we found that CTI-2 treatment significantly reduced breast cancer cell metastasis in vivo and in vitro. Notably, with the treatment of CTI-2 in breast cancer cells, the expression level of E-cadherin increased, while the expression level of N-cadherin and vimentin decreased. In addition, after CTI-2 treatment, those outflow levels for p-ERK, p-p38, and p-JNK diminished, while no significant changes in the expression levels of ERK, JNK, or p38 were observed. Our conclusion suggested that CTI-2 inhibits the epithelial-mesenchymal transition (EMT) of breast carcinoma cells by inhibiting the activation of the mitogen-activated protein kinase (MAPK) signaling pathway, thereby inhibiting the metastasis of breast tumor cells. Therefore, we believe that CTI-2 is another candidate for breast tumor medication.Junfeng KeWenzhao HanFanwei MengFeng GuoYuhong WangLiping WangMDPI AGarticlebreast cancermetastasisEMTMAPKBiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12229, p 12229 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer metastasis EMT MAPK Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	breast cancer metastasis EMT MAPK Biology (General) QH301-705.5 Chemistry QD1-999 Junfeng Ke Wenzhao Han Fanwei Meng Feng Guo Yuhong Wang Liping Wang CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway
description	Although some breast cancer patients die due to tumor metastasis rather than from the primary tumor, the molecular mechanism of metastasis remains unclear. Therefore, it is necessary to inhibit breast cancer metastasis during cancer treatment. In this case, after designing and synthesizing CTI-2, we found that CTI-2 treatment significantly reduced breast cancer cell metastasis in vivo and in vitro. Notably, with the treatment of CTI-2 in breast cancer cells, the expression level of E-cadherin increased, while the expression level of N-cadherin and vimentin decreased. In addition, after CTI-2 treatment, those outflow levels for p-ERK, p-p38, and p-JNK diminished, while no significant changes in the expression levels of ERK, JNK, or p38 were observed. Our conclusion suggested that CTI-2 inhibits the epithelial-mesenchymal transition (EMT) of breast carcinoma cells by inhibiting the activation of the mitogen-activated protein kinase (MAPK) signaling pathway, thereby inhibiting the metastasis of breast tumor cells. Therefore, we believe that CTI-2 is another candidate for breast tumor medication.
format	article
author	Junfeng Ke Wenzhao Han Fanwei Meng Feng Guo Yuhong Wang Liping Wang
author_facet	Junfeng Ke Wenzhao Han Fanwei Meng Feng Guo Yuhong Wang Liping Wang
author_sort	Junfeng Ke
title	CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway
title_short	CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway
title_full	CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway
title_fullStr	CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway
title_full_unstemmed	CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway
title_sort	cti-2 inhibits metastasis and epithelial-mesenchymal transition of breast cancer cells by modulating mapk signaling pathway
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/76c7fe7952a64911a36554eb0253dfcd
work_keys_str_mv	AT junfengke cti2inhibitsmetastasisandepithelialmesenchymaltransitionofbreastcancercellsbymodulatingmapksignalingpathway AT wenzhaohan cti2inhibitsmetastasisandepithelialmesenchymaltransitionofbreastcancercellsbymodulatingmapksignalingpathway AT fanweimeng cti2inhibitsmetastasisandepithelialmesenchymaltransitionofbreastcancercellsbymodulatingmapksignalingpathway AT fengguo cti2inhibitsmetastasisandepithelialmesenchymaltransitionofbreastcancercellsbymodulatingmapksignalingpathway AT yuhongwang cti2inhibitsmetastasisandepithelialmesenchymaltransitionofbreastcancercellsbymodulatingmapksignalingpathway AT lipingwang cti2inhibitsmetastasisandepithelialmesenchymaltransitionofbreastcancercellsbymodulatingmapksignalingpathway
_version_	1718411869719363584

CTI-2 Inhibits Metastasis and Epithelial-Mesenchymal Transition of Breast Cancer Cells by Modulating MAPK Signaling Pathway

Ejemplares similares